{"id":"W4417421081","doi":"10.3390/ph18121898","title":"First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours","year":2025,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; SignalChem (Canada)","funders":"","keywords":"Pharmacokinetics; Clinical trial; Adverse effect; Bioavailability; Drug; Tolerability; Phases of clinical research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001603707,0.001880572,0.001647564,0.0003817908,0.0006259194,0.0008803445,0.0007471026,0.001322998,0.005279773],"category_scores_gemma":[0.0005616969,0.0005702431,0.0009868213,0.000317988,0.0009908727,0.000863259,0.0004322355,0.002750489,0.001002716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006416,"about_ca_system_score_gemma":0.001922424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001008387,"about_ca_topic_score_gemma":0.003437361,"domain_scores_codex":[0.9995516,0.0001661533,0.00002344868,0.00008817679,0.00004259874,0.0001278803],"domain_scores_gemma":[0.9994243,0.00006416353,0.0001096604,0.00003917842,0.00003922627,0.0003235486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6204358,0.1256215,0.006122566,0.001479306,0.001136351,0.0007275427,0.0006508788,0.002788512,0.1284963,0.0004159587,0.008308624,0.1038167],"study_design_scores_gemma":[0.2417809,0.7388869,0.007809516,0.00002919099,0.0002279663,0.0003846695,0.00004989631,0.0009310993,0.006114999,0.0001679779,0.003591154,0.00002573095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886786,0.002175914,0.0006935716,0.0004890987,0.0001303194,0.004045055,0.00167118,0.0001680933,0.001948074],"genre_scores_gemma":[0.9867038,0.001239053,0.001993697,0.0008059905,0.0001604281,0.002843151,0.002329917,0.00003949791,0.0038845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005279773,"threshold_uncertainty_score":0.01766264,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03782600799213566,"score_gpt":0.4090290512616684,"score_spread":0.3712030432695327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}